GlaxoSmithKline plc (GSK) Expected to Post Earnings of $0.78 Per Share

Share on StockTwits

Equities research analysts expect GlaxoSmithKline plc (NYSE:GSK) to report $0.78 earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for GlaxoSmithKline’s earnings. GlaxoSmithKline posted earnings per share of $0.70 during the same quarter last year, which would suggest a positive year over year growth rate of 11.4%. The company is expected to issue its next earnings results on Wednesday, July 25th.

According to Zacks, analysts expect that GlaxoSmithKline will report full-year earnings of $2.84 per share for the current year, with EPS estimates ranging from $2.73 to $3.05. For the next year, analysts forecast that the company will report earnings of $2.98 per share, with EPS estimates ranging from $2.87 to $3.22. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover GlaxoSmithKline.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.02). GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. The company had revenue of $10.04 billion during the quarter, compared to analyst estimates of $10.26 billion.

GSK has been the subject of a number of recent research reports. Cowen reiterated a “hold” rating and issued a $40.00 target price on shares of GlaxoSmithKline in a research note on Thursday, February 15th. Zacks Investment Research lowered GlaxoSmithKline from a “hold” rating to a “sell” rating in a research note on Wednesday, February 21st. Morgan Stanley upgraded GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a research note on Thursday, March 22nd. Deutsche Bank reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Wednesday, March 28th. Finally, BNP Paribas upgraded GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 4th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $40.21.

A number of institutional investors and hedge funds have recently modified their holdings of GSK. We Are One Seven LLC boosted its holdings in GlaxoSmithKline by 185.1% in the first quarter. We Are One Seven LLC now owns 2,677 shares of the pharmaceutical company’s stock valued at $105,000 after purchasing an additional 1,738 shares during the last quarter. Adviser Investments LLC bought a new position in GlaxoSmithKline during the 1st quarter worth approximately $117,000. Toronto Dominion Bank lifted its holdings in GlaxoSmithKline by 133.3% during the 1st quarter. Toronto Dominion Bank now owns 3,150 shares of the pharmaceutical company’s stock worth $123,000 after buying an additional 1,800 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in GlaxoSmithKline during the 1st quarter worth approximately $135,000. Finally, Wealthcare Advisory Partners LLC lifted its holdings in GlaxoSmithKline by 80.8% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 3,570 shares of the pharmaceutical company’s stock worth $139,000 after buying an additional 1,595 shares during the last quarter. 11.09% of the stock is owned by hedge funds and other institutional investors.

Shares of GSK stock traded up $0.80 during trading hours on Friday, reaching $41.94. The company had a trading volume of 3,496,218 shares, compared to its average volume of 3,474,794. The company has a debt-to-equity ratio of 3.90, a quick ratio of 0.40 and a current ratio of 0.61. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.44. The firm has a market cap of $102.13 billion, a P/E ratio of 14.56, a price-to-earnings-growth ratio of 2.20 and a beta of 0.83.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 12th. Investors of record on Friday, May 11th will be issued a $0.5298 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 5.05%. The ex-dividend date of this dividend is Thursday, May 10th. GlaxoSmithKline’s dividend payout ratio is currently 72.92%.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Get a free copy of the Zacks research report on GlaxoSmithKline (GSK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Axiom Price Reaches $0.0078 on Exchanges
Axiom Price Reaches $0.0078 on Exchanges
Starta Hits 24-Hour Trading Volume of $0.00
Starta Hits 24-Hour Trading Volume of $0.00
Zacks: Brokerages Expect MTS Systems Co.  Will Announce Earnings of $0.63 Per Share
Zacks: Brokerages Expect MTS Systems Co. Will Announce Earnings of $0.63 Per Share
Obalon Therapeutics  Getting Somewhat Positive Media Coverage, Study Shows
Obalon Therapeutics Getting Somewhat Positive Media Coverage, Study Shows
Novus Therapeutics  Receives News Impact Score of 0.16
Novus Therapeutics Receives News Impact Score of 0.16
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc  This Quarter
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc This Quarter


Leave a Reply

 
© 2006-2018 Zolmax.